Magnitude of Osteoarthritis disadVantage on pEoples liveS (MOVES)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01423097
First received: August 24, 2011
Last updated: October 9, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Estimate the prevalence of self-reported osteoarthritis and its characterization in adults over 45 years of age:
- Characterization of self-reported patients with OA (socio-demographic, comorbidities, VAS for intensity of pain)
- Characterization of OA diagnosis in patients with self-reported OA
- Impact of self-reported OA in the working abilities, quality of life and functionality (SF-12 v2.0)
- Characterization of treatment approaches (therapeutic and non-therapeutic) for self-reported patients with OA
- Patient perception of impact of OA in its life and importance given to disease
| Condition |
|---|
|
Osteoarthritis |
| Study Type: | Observational |
| Study Design: | Observational Model: Ecologic or Community Time Perspective: Cross-Sectional |
| Official Title: | Magnitude of Osteoarthritis disadVantage on pEoples liveS |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- Estimate the prevalence of self-reported osteoarthritis (OA) in adults over 45 years of age by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Characterization of self-reported patients with OA by collecting socio-demographic information through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
- Characterization of self-reported patients with OA by collecting comorbidities information through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
- Characterization of self-reported patients with OA by collecting information for intensity of pain through direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
- Characterization of OA diagnosis in patients with self-reported OA by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
- Impact of self-reported OA in the working abilities, quality of life and functionality using Questionnaire SF-12 v2.0 [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: No ]
- Patient perception of impact of OA in its life and importance given to disease by direct interview. [ Time Frame: Single interview at the only one patient contact ] [ Designated as safety issue: Yes ]
| Enrollment: | 1015 |
| Study Start Date: | September 2011 |
| Study Completion Date: | November 2011 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
Magnitude of Osteoarthritis disadvantage on peoples lives.
Eligibility| Ages Eligible for Study: | 45 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
community sample
Criteria
Inclusion Criteria:
- Adults over 45 years old with self-reported osteoarthritis
Exclusion Criteria:
- NA
Contacts and Locations More Information
No publications provided
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT01423097 History of Changes |
| Other Study ID Numbers: | NIS-RPO-XXX-2011/2 |
| Study First Received: | August 24, 2011 |
| Last Updated: | October 9, 2012 |
| Health Authority: | Portugal: Data Protection National Committee |
Keywords provided by AstraZeneca:
|
osteoarthritis symptoms |
Additional relevant MeSH terms:
|
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013